HC Wainwright Downgrades Humanigen On Disappointing COVID-19 Study - What's Next

• HC Wainwright downgraded Humanigen Inc (NASDAQ: HGEN) to Neutral from Buy and removed the price target based on the removal of COVID-19 from lenzilumab projections and the lack of near-term catalysts beyond COVID-19 that could potentially drive the shares.

• The analyst looks to reassess valuation as the lenzilumab opportunities in graft vs. host disease, chronic myelomonocytic leukemia, and CAR-T prophylaxis can potentially be important drivers for the shares.

• Related: Humanigen's Lenzilumab Disappoints In NIH-Backed COVID-19 Study.

• HC wainwright says that though the update was unexpected and discouraging, the endemic nature of COVID-19 means the demand for additional studies for variant-targeted treatments is likely to stay.

• "We expect the company to deemphasize its COVID-19 program and strategically realign its focus on company-sponsored and partner-sponsored programs," the analyst added.

• If the COVID-19 program were to proceed, a much larger study would be required, most likely in someone else's hands.

• The analyst notes that enrollment in the Phase 2/3 RATinG trial of patients at high and intermediate risk for acute GvHD is on track for this quarter. Also, initial data from a Phase 2/3 study of lenzilumab in CMML (PREACH-M) is anticipated in early 2023.

• Price Action: HGEN shares are down 79.8% at $0.60 during the market session on the last check Wednesday.

Latest Ratings for HGEN

Date	Firm	Action	From	To
Sep 2021	Jefferies	Downgrades	Buy	Hold
Sep 2021	JP Morgan	Downgrades	Neutral	Underweight
Sep 2021	HC Wainwright & Co.	Maintains		Buy

View More Analyst Ratings for HGEN

View the Latest Analyst Ratings

See more from Benzinga

• The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program

• Humanigen's Lenzilumab Disappoints In NIH-Backed COVID-19 Study

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.